Top Biomarkers Companies

Global Biomarkers Market size was valued at USD 58.2 billion in 2023 and is poised to grow from USD 65.36 billion in 2024 to USD 165.33 billion by 2032, growing at a CAGR of 12.3% during the forecast period (2025-2032).

Hoffmann-La Roche AG (Switzerland), Thermo Fisher Scientific Inc. (United States), Agilent Technologies, Inc. (United States), QIAGEN N.V. (Netherlands), Bio-Rad Laboratories, Inc. (United States), Merck & Co., Inc. (United States), PerkinElmer, Inc. (United States), Illumina, Inc. (United States), BD (Becton, Dickinson and Company) (United States), Myriad Genetics, Inc. (United States), Siemens Healthineers AG (Germany), Danaher Corporation (United States), Biomerieux SA (France), Waters Corporation (United States), Abbott Laboratories (United States), Sysmex Corporation (Japan), Bio-Techne Corporation (United States), Charles River Laboratories International, Inc. (United States), Eurofins Scientific SE (Luxembourg), Pacific Biomarkers (United States)

Increasing prevalence of chronic diseases such as cancer, cardiovascular diseases, and neurological disorders is among the major drivers of the biomarkers market. Detection and monitoring of these diseases are highly dependent on the identification of biomarkers, which enable early treatment and targeted therapy. As with the emphasis of health care systems globally turned towards preventive therapy, biomarkers have an important use in offering information about the onset of conditions as well as vulnerability to treatment. This demand also spurs demand for biomarker diagnostics and prognosis, stimulating investments in biomarker research as well as development of biomarker technology, thereby increasing the scope and applications of the market.

Liquid biopsy is being quickly embraced as a quick, effective method of biomarker detection and monitoring, primarily in oncology. Liquid biopsy measures circulating tumor DNA (ctDNA) or other molecules found in the blood to facilitate early cancer detection, real-time treatment monitoring, and detection of resistance mutations. Ease of use compared to traditional tissue biopsies drives global clinical adoption. Enhanced sensitivity and specificity, and AI analytics integration, are optimizing liquid biopsies' performance. This is pushing expansion into non-cancer indications to other diseases, stimulating growth and investment in liquid biopsy platforms.

North America dominates the world biomarkers market with strong healthcare infrastructure, high R&D spending, and rampant incidence of chronic diseases. The U.S. market alone would be valued at USD 124.49 billion by 2034 with a CAGR of 15.22%. The drivers on their list are genomics, proteomics, and bioinformatics advances, which would facilitate the discovery of new biomarkers. Government programs such as the Cancer Moonshot and Precision Medicine Initiative propel market growth by investing in biomarker R&D. The presence of large-scale biotech companies and favorable regulative frameworks also support biomarker-based therapeutics and diagnostics commercialization.